HRS-7085

Phase 2Small molecule

SShandong Suncadia Medicine Co., Ltd.

HRS-7085 is one of 51 small molecule programs targeting Inflammatory Bowel Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Inflammatory Bowel DiseaseRecruiting

Inflammatory Bowel DiseasePhase 2

Recruiting

Competition

Competitive Landscape

62 competitors in Inflammatory Bowel Disease

#DrugCompanyPhaseTrials

Remicade

Johnson & Johnson

Approved

17 2

Skyrizi

AbbVie

Approved

3 3

Dificlir

Merck & Co.

Approved

1 4

Humira

RRanbaxy Laboratories Limited

Approved

7 5

Mounjaro

Elavil

Calciferol

Vancocin

HHikma Pharmaceuticals LLC

Approved

1 9

Spravato

WWim Janssens

Approved

1 10

Aplenzin

GGlaxo Dba Glaxosmithkline

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Inflammatory Bowel Disease

NCT07229950

Clinical

Trials by Indication[1]

Clinical Trial1 trial

A Randomized, Double-Blind, Dose-Escalation, Placebo-Controlled Phase I Clinical Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Oral Doses of HRS-7085 Tablets in Healthy Subjects, With Assessment of Food Effects

Unknown status·SShandong Suncadia Medicine Co., Ltd.·Phase 1·NCT06175949·70 enrolled

Trial1 trial

A Trial of HRS-7085 Tablet in Healthy Participants With and Without Food Effect.

Completed·AAtridia Pty Ltd.·Phase 1·NCT05638347·16 enrolled

Inflammatory Bowel Disease1 trial

A Phase 2 Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HRS-7085 Tablets in Patients With Inflammatory Bowel Disease

Recruiting·SShandong Suncadia Medicine Co., Ltd.·Phase 2·NCT07229950·66 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for HRS-7085. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HRS-7085 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HRS-7085. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shandong Suncadia Medicine Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SShandong Suncadia Medicine Co., Ltd.

HRS-7085

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Clinical Trial1 trial

Trial1 trial

Inflammatory Bowel Disease1 trial

References

Drug Info

Quick Facts

Related News